# US 2010/0144711 A1 · Pharmaceutical composition for oral administration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0144711 A1
- Document ID: US20100144711A1
- Status: Published application
- Kind: A1
- Application number: 12/568,342
- Filed: 2009-09-28
- Published: 2010-06-10
- Earliest claimed: 2008-09-30
- Assignees: Astellas Pharma Inc.
- Inventors: Shinsuke Oba; Takehiko Yasuji; Tadashi Hakomori; Kazuhiro Sako
- Web page: https://patentgrep.com/patent/US20100144711A1

## CPC

- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition for oral administration, comprising 3-hydroxy-N1-(4-methoxybenzoyl)-N2-[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]-1,2-phenylenediamine or a pharmaceutically acceptable salt thereof, and hydroxypropyl cellulose having a viscosity of approximately 6 mPa·S (inclusive) to approximately 150 mPa·S (exclusive) in a 2% aqueous solution at 20° C., or a viscosity of 75 mPa·S (inclusive) to 400 mPa·S (inclusive) in a 5% aqueous solution at 25° C., and a process of manufacturing the pharmaceutical composition for oral administration are disclosed.

## Claims

### Claim 1

A pharmaceutical composition for oral administration, comprising 3-hydroxy-N1-(4-methoxybenzoyl)-N2-[4-(4-methyl-1, 4-diazepan-1-yl)benzoyl]-1,2-phenylenediamine or a pharmaceutically acceptable salt thereof, and hydroxypropyl cellulose having a viscosity of approximately 6 mPa·S (inclusive) to approximately 150 mPa·S (exclusive) in a 2% aqueous solution at 20° C., or a viscosity of 75 mPa·S (inclusive) to 400 mPa·S (inclusive) in a 5% aqueous solution at 25° C.

### Claim 2 (depends on 1)

The pharmaceutical composition for oral administration according to claim 1, wherein the viscosity of hydroxypropyl cellulose is approximately 6 mPa·S (inclusive) to approximately 10 mPa·S (inclusive) in a 2% aqueous solution at 20° C.

### Claim 3 (depends on 1)

The pharmaceutical composition for oral administration according to claim 1, wherein the amount of hydroxypropyl cellulose is approximately 2 w/w % to approximately 720 w/w % with respect to the amount of 3-hydroxy-N1-(4-methoxybenzoyl)-N2-[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]-1,2-phenylenediamine or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The pharmaceutical composition for oral administration according to claim 1, wherein the amount of hydroxypropyl cellulose is approximately 4 w/w % to approximately 360 w/w % with respect to the amount of 3-hydroxy-N1-(4-methoxybenzoyl)-N2-[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]-1,2-phenylenediamine or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The pharmaceutical composition for oral administration according to claim 1, wherein the amount of hydroxypropyl cellulose is approximately 7 w/w % to approximately 25 w/w % with respect to the amount of 3-hydroxy-N1-(4-methoxybenzoyl)-N2-[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]-1,2-phenylenediamine or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The pharmaceutical composition for oral administration according to claim 1, characterized in that the composition is disintegrated within 5 minutes.

### Claim 7

A process of manufacturing a pharmaceutical composition for oral administration, comprising mixing 3-hydroxy-N1-(4-methoxybenzoyl)-N2-[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]-1,2-phenylenediamine or a pharmaceutically acceptable salt thereof with hydroxypropyl cellulose having a viscosity of approximately 6 mPa·S (inclusive) to approximately 150 mPa·S (exclusive) in a 2% aqueous solution at 20° C., or a viscosity of 75 mPa·S (inclusive) to 400 mPa·S (inclusive) in a 5% aqueous solution at 25° C.

### Claim 8 (depends on 7)

The process according to claim 7, wherein the viscosity of hydroxypropyl cellulose is approximately 6 mPa·S (inclusive) to approximately 10 mPa·S (inclusive) in a 2% aqueous solution at 20° C.

### Claim 9 (depends on 7)

The process according to claim 7, wherein the amount of hydroxypropyl cellulose is approximately 2 w/w % to approximately 720 w/w % with respect to the amount of 3-hydroxy-N1-(4-methoxybenzoyl)-N2-[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]-1,2-phenylenediamine or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 7)

The process according to claim 7, wherein the amount of hydroxypropyl cellulose is approximately 4 w/w % to approximately 360 w/w % with respect to the amount of 3-hydroxy-N1-(4-methoxybenzoyl)-N2-[4-(4-methyl-1, 4-diazepan-1-yl)benzoyl]-1,2-phenylenediamine or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 7)

The process according to claim 7, wherein the amount of hydroxypropyl cellulose is approximately 7 w/w % to approximately 25 w/w % with respect to the amount of 3-hydroxy-N1-(4-methoxybenzoyl)-N2-[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]-1,2-phenylenediamine or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 7)

The process according to claim 7, characterized in that the composition is disintegrated within 5 minutes.

### Claim 13

(canceled)
